TB-500 Fragments, BPC-157, Regen Peptide Stacks, N-Acetyl Epitalon, and GHRP-2 vs GHRP-6: A Clinical Reference Guide

The direct answer

TB-500 (a fragment of thymosin beta-4), BPC-157, GHRP-2, GHRP-6, and N-acetyl epitalon are distinct peptides with plausible, mechanistically coherent effects on tissue repair, gut mucosa, growth hormone release, and cellular aging pathways, but none is FDA-approved for human therapeutic use, and the human clinical trial evidence behind each is thin or absent as of 2025. The FDA has identified BPC-157 by name as a substance with safety concerns that preclude routine compounding. The realistic clinical question is not which combination "works best," since no trial has tested any of these peptides in combination, but whether the preclinical mechanism, the absence of human safety data, and the unregulated compounding supply chain justify use in a given patient given their specific injury, goals, and risk tolerance.

Entity clarification

TB-500 is not the same molecule as full-length thymosin beta-4; it is a shorter synthetic peptide intended to reproduce the actin-binding activity of the parent protein's active region. BPC-157 is an unrelated synthetic pentadecapeptide loosely based on a fragment described in gastric protective research, not a fragment of thymosin beta-4. GHRP-2 and GHRP-6 are both synthetic hexapeptide growth hormone secretagogues that act on the ghrelin receptor (GHSR-1a), but they are chemically distinct molecules with different receptor selectivity profiles. Epitalon and N-acetyl epitalon are tetrapeptides unrelated in structure to the other four peptides; the "N-acetyl" prefix denotes a chemical modification, not a different drug class. None of these agents is a growth hormone releasing hormone (GHRH) analog, and none is the same as human growth hormone itself.

What TB-500 is and what its evidence actually shows

TB-500 is described in compounding and wellness literature as the sequence Ac-LKKTETQ, corresponding to a region of the 43-amino-acid protein thymosin beta-4, which binds monomeric (G-) actin and participates in cytoskeletal remodeling relevant to cell migration and wound closure. This mechanism is biologically plausible and is consistent with a substantial published literature on full-length thymosin beta-4 in cardiac and skin repair models in rodents.

What is established: thymosin beta-4 has documented actin-binding activity and has been studied for decades in animal wound-healing and cardiac-repair models. What is plausible but unproven: that the shortened synthetic fragment marketed as "TB-500" reproduces the parent protein's activity at the doses used in compounding protocols, and that subcutaneous injection in humans produces a clinically meaningful acceleration of tendon, muscle, or cardiac repair. What is not established: any completed human efficacy trial of TB-500 for a specific musculoskeletal or cardiac indication. This draft could not verify a specific figure for infarct size reduction, cytokine suppression percentage, or blood pressure effect against a checked primary source, so those numbers are omitted rather than restated as fact. A reader encountering such figures in marketing material should ask the source to produce the underlying study before treating the number as reliable.

The 2.0 to 2.5 mg twice-weekly subcutaneous dosing pattern described in this article reflects protocols used by compounding pharmacies and practitioners, not a dose derived from a controlled human trial. No standard loading or maintenance schedule has been validated in peer-reviewed human research.

BPC-157: mechanism, evidence, and the regulatory flag

BPC-157 is a synthetic 15-amino-acid peptide studied predominantly by one research group's rodent models of gastric mucosal protection, tendon healing, and gut permeability. The proposed mechanisms include effects on VEGF-related angiogenic signaling and protection of gastric mucosa against NSAID-induced injury in animal studies. These are consistent, repeated findings within that body of preclinical work, but independent replication in other laboratories and in human subjects is limited, and no completed phase I human pharmacokinetic or safety trial was identified for this draft.

The FDA has publicly identified BPC-157 as a substance that raises safety concerns sufficient to preclude its inclusion in compounded drug products outside an approved investigational pathway, according to regulatory guidance. This is a regulatory judgment, not a peer-reviewed efficacy finding, but it is the most authoritative statement currently available about BPC-157's regulatory standing, and it should carry more weight for a prescribing decision than any preclinical mechanism paper.

Oral and subcutaneous BPC-157 are both used in compounding practice; oral use is generally framed around local gastrointestinal effects, while subcutaneous use is framed around systemic tissue repair, but human pharmacokinetic data distinguishing the two routes were not verifiable for this draft. Reported daily doses in wellness and compounding literature range from roughly 250 to 500 micrograms, but this figure reflects practice pattern rather than a dose-finding trial result.

A decision framework for evaluating a proposed regen peptide stack

The peptides in this article are frequently marketed together as a "regen stack," but no trial has tested any combination of them, and each carries a different evidence and regulatory profile. The table and questions below are meant to help a clinician or patient decide whether a specific proposed protocol is reasonable to consider, rather than to recommend a specific stack.

Decision rule for a clinician or informed patient:

1. If a component peptide has a specific regulatory safety flag (currently BPC-157), that flag should outweigh any preclinical mechanism argument for using it outside a monitored, individualized clinical context.
2. If the evidence for a peptide is confined to rodent or in vitro data, treat the mechanism as a hypothesis, not as a reason to expect a specific magnitude of human benefit.
3. If a stack combines a GHRP with any peptide, obtain baseline IGF-1 and morning cortisol before starting, because the growth hormone secretagogue component, not the repair peptides, is the piece with the most established human endocrine effect and the most plausible monitoring need.
4. If the patient has active malignancy, a strong family history of hormone-sensitive cancer, an eating disorder, or a BMI in the underweight range, the GHRP component of any stack needs individualized review before proceeding, given its known endocrine and appetite effects.
5. If a compounding pharmacy cannot describe its sterility testing and potency verification process for a specific peptide, that is a stop point independent of the underlying science.

N-acetyl epitalon: telomerase claims and what remains unverified

Epitalon (Ala-Glu-Asp-Gly) and its acetylated form are tetrapeptides studied largely by a single research group associated with pineal gland biology and aging. The most frequently cited claim, that epitalon activates telomerase and lengthens telomeres in cultured human cells, originates from that group's own published cell-culture work; this draft could not independently verify the specific percentage increase or exposure duration reported in secondary summaries, and that number should be treated as unconfirmed rather than restated as an established fact. Separate small studies from the same research tradition have examined effects on melatonin and cortisol secretion in older subjects, but sample sizes were small and independent replication outside that research group is limited.

What is established: epitalon and related tetrapeptides have been studied for several decades in a defined research niche focused on pineal and aging biology. What is plausible but unproven: that in vitro telomerase activation translates into a measurable clinical anti-aging effect in humans at the doses used in compounding protocols. What is not established: any regulatory-grade or independently replicated human trial demonstrating a clinical benefit from N-acetyl epitalon. The 10 mg nightly, 10-to-20-day cycle pattern reflects compounding and longevity-clinic practice, not a validated dosing trial.

GHRP-2 vs GHRP-6: what is different enough to matter

GHRP-2 and GHRP-6 are both synthetic hexapeptides that activate the ghrelin receptor (GHSR-1a) and stimulate pulsatile growth hormone release, a mechanism that is well characterized in the endocrine pharmacology literature going back to early GHRP research. The clinically relevant distinction reported across this literature is that GHRP-6 produces a stronger appetite-stimulating effect through peripheral ghrelin signaling than GHRP-2 does at comparable doses. This makes GHRP-6 a more plausible fit for wasting or cachexia contexts where appetite stimulation is a goal, and GHRP-2 a more plausible fit where a patient wants GH-axis stimulation without a strong hunger effect. This draft could not verify the specific fold-increase or percentage figures for GH pulse magnitude or appetite increase attributed to each peptide against a checked primary source, so those numbers are omitted; a prescriber relying on them should request the original study.

GHRP-2 is documented in the pharmacology literature to raise cortisol modestly and transiently after injection, which is the basis for checking a baseline morning cortisol before starting a GHRP protocol, particularly in patients with known or suspected adrenal dysfunction. Combining a GHRP with a GHRH analog is described in the endocrine literature as producing a larger GH pulse than either peptide alone, though exact magnitude estimates vary by study and dose and were not independently verified for this draft.

Safety, monitoring, and when this is not a self-directed decision

None of the five peptides discussed here holds FDA approval for the tissue-repair, anti-aging, or physique-related uses described in wellness marketing. GHRP-2 (pralmorelin) has an approved diagnostic use in Japan for GH-deficiency testing, which is a different indication and dosing context than repeated therapeutic injection. Compounded peptide products, including all five discussed here, are not subject to the batch sterility and potency testing that FDA-approved drugs undergo, and the FDA has specifically flagged BPC-157 as a safety concern for compounding, according to regulatory guidance.

Reasonable baseline monitoring for a patient and prescriber considering a GHRP-containing protocol includes fasting IGF-1 and morning cortisol before starting, with IGF-1 rechecked several weeks into treatment. Growth hormone secretagogues raise IGF-1, and elevated circulating IGF-1 has been associated with increased cancer risk in some epidemiological literature; this is a reason for caution and monitoring, not a claim that therapeutic secretagogue use has been shown to cause cancer. Patients with active malignancy, a strong family history of hormone-sensitive cancer, uncontrolled diabetes, or adrenal disease should have these protocols reviewed individually rather than following a generic cycle template. Anyone with acute chest pain, signs of infection at an injection site, unexplained rapid weight change, or new neurological symptoms while using any of these peptides needs urgent in-person evaluation rather than peptide-forum advice.

Evidence boundary summary

Established: thymosin beta-4's actin-binding biology, BPC-157's repeated rodent-model findings from a concentrated research literature, the basic ghrelin-receptor pharmacology shared by GHRP-2 and GHRP-6, and epitalon's in vitro telomerase findings from its originating research group. Plausible but unproven: that any of these translate into the specific human clinical benefits claimed in compounding and wellness marketing at the doses commonly sold. Not established: FDA approval for any of these five peptides for the indications discussed, a completed human efficacy trial for TB-500 or BPC-157 in tissue repair, or independent replication of the epitalon telomerase findings outside the originating group. Regulatory status can change; readers should check current FDA guidance rather than relying on this page's 2025 snapshot indefinitely.